| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2017: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
Poly (ADP-ribose) polymerase inhibitors (PARPi) effectively kill homologous recombination deficient tumor cells through the concept of synthetic lethality. However, PARPi resistance frequently occurs, and therefore additional strategies that synergize with PARPi to enhance anti-tumor activity are necessary. To develop approaches for enhancing the effectiveness of PARPi, we demonstrated a microRNA array analysis to identify targets affected by treating medulloblastoma (MB) cells with the PARPi olaparib. We found that the expression level of miR-X, miR-Y, and miR-Z were selectively down-regulated in Brca2-deficient MB cells after olaparib treatment. These results suggest that miR-X, miR-Y, and miR-Z upregulation may improve the chemotherapeutic efficacy of olaparib in BRCA-proficient cancer.
|
